A Study to Assess the Bioavailability and Effect of Food of BMS-986419 Immediate-release Tablet Formulation in Healthy Adult Participants - CN007-1001
Updated: 28 August, 2023 | ClinicalTrials.gov
Print Friendly Summary
Inclusion Criteria: - Healthy male and female participants without clinically significant deviation from normal, as determined by the investigator, in medical history, physical examination, vital signs, 12-lead ECG, and clinical laboratory evaluations. - Body mass index (BMI) of 18.0 to 32.0 kilograms per meter squared (kg/m^2), inclusive, and body weight ≥ 50 kg. - A female participant is eligible to participate if she is a woman not of childbearing potential (WNOCBP) Exclusion Criteria: - Any significant acute or chronic medical illness (eg, history of intracranial or intraspinal hemorrhage, CNS lesions, recent bacterial or fungal meningitis, etcetera) as determined by the investigator. - Current or recent (within 3 months of study intervention administration) gastrointestinal disease that could affect the absorption, distribution, metabolism, and excretion of study intervention (for example, bariatric procedure). - History of Gilbert's syndrome. - Women who are of childbearing potential and women who are breastfeeding.